Corbus Reports 5% Mean Weight Loss at 60 mg in Phase 1b Study
Corbus said all three CRB-913 doses in its Phase 1b CANYON-1 study produced statistically significant weight loss. The 60 mg dose achieved mean weight loss of 5% at 12 weeks; adverse-event-related discontinuation across cohorts was 8.3%.
Corbus reported statistically significant weight loss at all three CRB-913 doses in its Phase 1b CANYON-1 study; the 60 mg dose achieved mean weight loss of 5% at 12 weeks. AE-related discontinuation across cohorts was 8.3%.Material DetailsContext by AI AnalystThis is an early clinical-stage update…